Back to first-pass browser

First-pass extracted concept

logic-gated CARs

Candidate: concept label2 source documents4 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

Logic-gated CARs are described as an engineering strategy that improves specificity and safety in solid-tumor CAR T therapy.

Source 1DOIPubMed

Logic-gated CARs are described as CAR strategies that improve selectivity through dual-antigen recognition or conditional activation.

Source 2DOIPubMed

Resources required

The abstract supports that these systems require designs implementing dual-antigen recognition or conditional activation.

Source 2DOIPubMed

What problem it solves

The abstract frames these designs as part of efforts to overcome major barriers including toxicity and poor selectivity.

Source 1DOIPubMed

They are presented as a way to address limited AML-specific targeting and reduce imprecise recognition.

Source 2DOIPubMed

What it does not solve

The abstract does not show that logic-gated CARs fully eliminate relapse or toxicity in AML.

Source 2DOIPubMed

Alternatives

The abstract contrasts logic-gated CARs with affinity-tuned CARs, multi-antigen targeting, gene editing, trafficking modifications, and extracellular matrix degradation strategies.

Source 1DOIPubMed

The abstract contrasts logic-gated CARs with drug-inducible or transient systems, pharmacologic or suicide switches, adapter CAR platforms, and alternative immune-cell platforms.

Source 2DOIPubMed

Evidence Snippets

Innovations such as affinity-tuned and logic-gated CARs improve specificity and safety.
Evidence 1Source 1DOIPubMedprovenance
Logic-gated CARs improve selectivity through dual-antigen recognition or conditional activation.
Evidence 2Source 2DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1capabilitysupports2025Source 2DOIPubMed

Logic-gated CARs improve selectivity through dual-antigen recognition or conditional activation.

Quoted textsource-backed
Logic-gated CARs improve selectivity through dual-antigen recognition or conditional activation.
Claim 2engineering strategy effectsupports2025Source 1DOIPubMed

Logic-gated CARs improve specificity and safety in CAR T cells for solid tumors.

Claim 3limitationsupports2025Source 2DOIPubMed

CAR T-cell therapy in AML has been limited by early relapses and severe toxicities.

Quoted textsource-backed
its application in AML has been limited by early relapses and severe toxicities
Claim 4mechanism or rationalesupports2025Source 2DOIPubMed

Most AML-associated surface antigens are also expressed on healthy hematopoietic stem and progenitor cells, creating risks of on-target/off-tumor toxicity and prolonged myeloablation.

Quoted textsource-backed
most AML-associated surface antigens are also expressed on healthy hematopoietic stem and progenitor cells, creating significant risks of on-target/off-tumor toxicity and prolonged myeloablation